These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 15876279)

  • 1. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
    Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
    Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis.
    Lormeau C; Soudan B; d'Herbomez M; Pigny P; Duquesnoy B; Cortet B
    Bone; 2004 Jun; 34(6):933-9. PubMed ID: 15193539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Mannazzu M; Falchi A; Sanna D; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
    AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of bone remodeling in the elderly subject: effects of vitamin D insufficiency and its correction.
    Brazier M; Kamel S; Maamer M; Agbomson F; Elesper I; Garabedian M; Desmet G; Sebert JL
    J Bone Miner Res; 1995 Nov; 10(11):1753-61. PubMed ID: 8592953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
    Gannagé-Yared MH; Fares F; Semaan M; Khalife S; Jambart S
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):652-8. PubMed ID: 16712667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are activated T cells regulators of bone metabolism in children with Crohn disease?
    Sylvester FA; Davis PM; Wyzga N; Hyams JS; Lerer T
    J Pediatr; 2006 Apr; 148(4):461-6. PubMed ID: 16647405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
    Hofbauer LC; Schoppet M; Christ M; Teichmann J; Lange U
    Rheumatology (Oxford); 2006 Oct; 45(10):1218-22. PubMed ID: 16574701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN; Kandemir N
    Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
    Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
    Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.